January 7, 2020  

Celloram is awarded $0.2M DOD Grant to improve Post-Trauma-Induced Osteoarthritis

Celloram was awarded a $0.2M grant from the U.S. Department of Defense to improve post-trauma induced osteoarthritis. Osteoarthritis is a leading cause of mobility-related disability and is usually induced by the gradual wearing-down of joint cartilage over time. Post-trauma induced osteoarthritis, or PTOA, is a subtype of osteoarthritis that develops after joint injury and therefore disproportionality effects a young population.

Many PTOA cases recover within 6 months, but some cases can develop into chronic disease. The activation of inflammatory mechanisms is thought to play an important role in the progression of acute to chronic disease, so early interventions are of interest. Celloram hopes that by applying its innovative cell therapy technologies that work with the power of the immune system, we can develop early-intervention therapies to treat this debilitating chronic condition.

January 3, 2020  

Dr. Liraz Levi joins as VP and Director of Scientific Operations, Small Molecule Program

Dr. Liraz Levi joins Celloram as VP and Director of Scientific Operations of our Small

Molecule Program. Dr. Levi completed her Ph.D. at The Hebrew University of

Jerusalem and previously served as a principal investigator in the Case Comprehensive

Cancer Center at Case Western Reserve University.

Dr. Levi’s research began with an interest in dietary nutrients and how they affect

molecular processes in the body. Her research has since expanded into how fatty acids

and other small molecules can enhance or disrupt the processes that regulate cancer

cells and metabolic diseases.

Dr. Levi is a welcome and valued addition to Celloram and our Small Molecule Program.